Rubella in Pregnancy: Management by Clinical Scenario

Risk of Fetal Damage by Gestational Age

"No congenital defects are associated with maternal infection after 20 weeks of gestation." — Creasy & Resnik's Maternal-Fetal Medicine

Step 1: Assess Immune Status (Routine Prenatal Screening)

• IgG positive (≥10–15 IU/mL) → immune; no further action needed for routine exposure
• IgG negative (non-immune/susceptible) → at risk; manage as detailed below

Scenario 1: Immune Mother (IgG Positive) — Exposed to Rubella

• Reassure — existing IgG antibodies confer protection in nearly all cases.
• Reinfection is very rare and usually asymptomatic. Rarely, reinfection has been associated with CRS in a very small number of cases.
• If reinfection is suspected: perform IgG avidity testing. Low-avidity IgG = recent primary infection; high-avidity IgG = past infection/remote reinfection (lower fetal risk).
• No vaccine, no immunoglobulin needed.

Scenario 2: Non-Immune (Susceptible) Mother — Exposed to Rubella, No Symptoms

1. Collect baseline serology immediately: rubella-specific IgG and IgM. Store sera for later batched testing.
2. If IgG absent → repeat serology at 2–3 weeks after exposure, testing concurrently with the earlier specimen.
3. If still negative → repeat again at 6 weeks after initial exposure.
4. Counsel the mother on the risk of fetal infection based on gestational age (see table above).

• IG does not prevent rubella infection after exposure and is not recommended as routine postexposure prophylaxis.
• It may modify or suppress symptoms, creating a false sense of security — infants with CRS have been born to mothers who received IG.
• IG (20 mL IM within 72 hours) should be considered only if the pregnant woman will not consider pregnancy termination under any circumstances — it may reduce but does not eliminate risk.

"Administration of immunoglobulin should be considered only if a pregnant woman who has been exposed to rubella will not consider termination of the pregnancy under any circumstances." — Harrison's Principles of Internal Medicine 22E

Scenario 3: Non-Immune Mother — Develops Confirmed Rubella

3A: Infection ≤12 Weeks Gestation (Highest Risk)

• Risk of CRS: 52–90% — fetal damage nearly certain if infected in the first trimester.
• Counsel extensively about the very high risk of CRS (cataracts, deafness, heart defects, microcephaly, neurocognitive impairment).
• Offer pregnancy termination (therapeutic abortion) — this is standard practice and should be offered in documented first-trimester rubella.
• If termination is declined:
  • Close fetal surveillance with serial ultrasound (look for IUGR, structural defects, hydrops).
  • Consider amniocentesis or CVS for rubella virus PCR for prenatal diagnosis.
  • Refer to maternal-fetal medicine specialist.
  • Coordinate with neonatology/genetics for delivery planning.

3B: Infection 13–20 Weeks Gestation (Intermediate Risk)

• Risk of CRS: ~16% — still meaningful, particularly for sensorineural hearing loss.
• Counsel about residual risk, especially of isolated hearing loss (can occur with infection up to 20 weeks).
• Offer prenatal diagnosis (amniocentesis for rubella PCR) if desired.
• Serial ultrasound monitoring.
• Pregnancy termination may still be offered but risk-benefit discussion becomes more nuanced.

3C: Infection After 20 Weeks (Low Risk)

• Fetal structural defects are rarely associated with infection after 20 weeks.
• Sensorineural hearing loss is the main residual risk and may still occur.
• Reassure that major structural CRS defects are unlikely.
• Supportive care for mother (antipyretics, rest, fluids).
• Neonatal audiological follow-up after delivery.

Scenario 4: Inadvertent MMR/Rubella Vaccination in Early Pregnancy

• Do NOT recommend termination. In follow-up studies of ~3,000 unknowingly vaccinated pregnant women, no infant was born with CRS.
• Live attenuated vaccine virus carries a theoretical risk only — no documented CRS cases have resulted.
• Counsel and reassure. Continue pregnancy with routine monitoring.
• Women should ideally wait 28 days after receiving rubella vaccine before becoming pregnant.

"Inadvertent rubella immunization is not an indication for pregnancy termination." — Creasy & Resnik's Maternal-Fetal Medicine

Scenario 5: Susceptible Mother — Postpartum (Not Exposed/Not Infected)

• Vaccinate with MMR in the immediate postpartum period (before discharge).
• Breastfeeding is not a contraindication to rubella vaccination.
• Advise the mother to avoid pregnancy for 28 days after vaccination.
• Immunizing children of pregnant women is safe — no evidence of transmission of vaccine virus from a vaccinated child to a susceptible adult.

Scenario 6: Newborn with Suspected/Confirmed CRS

• Rubella-specific IgM (present for up to 6–12 months after birth).
• Persistent IgG not declining at expected rate (twofold per month).
• RT-PCR from nasopharyngeal swab, throat swab, or urine (most reliable in first 6 months).

• Isolation — infant actively sheds virus for up to 1 year; only immune caregivers should provide care.
• Contact isolation recommended until at least 1 year of age.
• IV immunoglobulin (IVIG) for neonates with significant multisystem CRS involvement.
• Ophthalmology consult — screen for cataracts, glaucoma, retinopathy.
• Cardiology — surgical management of PDA or pulmonary artery stenosis as for other congenital heart disease.
• Audiology — sensorineural deafness (most common long-term disability; ≥80% of CRS infants). Early diagnosis critical; auditory amplification devices, ENT referral.
• Neurology/developmental pediatrics for neurocognitive assessment.
• Immunology — check IgG levels; a subgroup has hypogammaglobulinemia requiring IVIG therapy.
• Respiratory support if pneumonitis present (same as other viral pneumonitis).
• All suspected CRS cases must be reported to the CDC via county/state health departments.

CRS Classic Manifestations Summary

Key Principles Summary

• Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, pp. 1180–1182
• Harrison's Principles of Internal Medicine 22E (2025), pp. 1686–1688
• Goldman-Cecil Medicine, pp. 3563–3564
• Recent review: De Melo LC et al., "Congenital Rubella Syndrome in the Post-Elimination Era: Why Vigilance Remains Essential," J Clin Med 2025 [PMID: 40507747]; Al Beloushi M et al., "Congenital and Perinatal Viral Infections," Viruses 2024 [PMID: 39599813]